Publications and Presentations

Filter By:

Encorafenib

11/18/2014

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Phase 1b Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Tabernero, et al.

Binimetinib

09/29/2014

ESMO

Overall Survival and Biomarker Results From a Phase 2 Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma

C. M. L. van Herpen, et al.

Selumetinib

09/28/2014

ESMO

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Selumetinib

09/28/2014

ESMO Congress 2014 - Madrid, Spain

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Encorafenib

09/26/2014

ESMO Congress 2014 - Madrid, Spain

Ph Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF‐mutant melanoma

M. H. Taylor, et. al

Encorafenib

09/26/2014

ESMO Annual Meeting - Madrid, Spain

Encorafenib (LGX818), an Oral BRAF Inhibitor, in Patients With BRAF V600E Metastatic Colorectal Cancer: Results of Dose Expansion in an Open-Label, Phase 1 Study

C. Gomez-Roca, et. al

Filanesib

06/13/2014

European Hematology Association

Phase 1 Study of Filanesib (ARRY-520) with Bortezomib (BTZ) and Dexamethasone (dex) in Relapsed or Refractory Multiple Myeloma (RRMM)

A. Chari, et al.

Selumetinib

06/02/2014

American Society of Clinical Oncology Meeting

A Phase I Study of the MEK1 Inhibitor Selumetinib (AZD6244) Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PNs)

L. Marcus, et al.

Binimetinib

06/01/2014

American Society of Clinical Oncology Meeting

A Phase 1b/2 Study of LEE011 in Combination With Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma: Early Encouraging Clinical Activity

J. A. Sosman, et al.

Binimetinib

05/31/2014

American Society of Clinical Oncology Meeting

A Phase 1b Open-Label, Multicenter, Dose-Escalation and -Expansion Study of Orally Administered Binimetinib (MEK162) Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

D. Juric, et al.